一个基于人工智能的框架用于阿尔茨海默病的诊断从磁共振成像通过视频视觉变压器通过磁共振成像卷
Taymaz Akan1,2, Sait Alp3, Shenuarin Bhuiyan4
1Department of Medicine, Louisiana State University Health Sciences Center at Shreveport, Shreveport, LA, USA.
概括
这项研究介绍了ViTranZheimer,这是一种使用视频转换器的AI工具,用于从MRI扫描中早期诊断阿尔茨海默病 (AD). 它实现了98.6%的准确性,为神经退行性疾病检测提供了一个有前途的方法.
科学领域:
- 人工智能在医学中的应用
- 神经成像分析分析 神经成像分析
- 为医疗保健提供深度学习.
背景情况:
- 阿尔茨海默病 (AD) 是一种进展性神经退行性疾病,导致认知能力下降,对老年人口产生重大影响.
- 早期和准确的AD诊断对于及时干预和有效的疾病管理至关重要.
- 非侵入性成像生物标志物,特别是MRI,对于检测AD至关重要.
研究的目的:
- 开发一个先进的AI诊断框架,ViTranZheimer,用于改进阿尔茨海默病的分类.
- 为了利用视频视觉转换器来分析磁共振成像 (MRI) 卷.
- 通过深度学习提高AD检测的准确性和灵敏性.
主要方法:
- ViTranZheimer将MRI卷处理为视频序列,以捕捉片之间时间依赖.
- 该模型使用了视频视觉转换器 (ViViT) 架构,从ADNI数据集 (351次MRI扫描) 上从头开始训练.
- 使用准确度,精度,回忆,F1得分和AUC来评估性能,并与基线模型 (CNN-BiLSTM,ViT-BiLSTM) 进行统计比较.
主要成果:
- ViTranZheimer实现了98.6%的诊断准确度,超过了基线模型 (CNN-BiLSTM达到96.5%,ViT-BiLSTM达到97.5%).
- 该模型表现出卓越的精度,回忆和F1得分 (全部为0.97),ROC曲线下的面积 (AUC) 为0.99.
- 统计分析证实了显著的性能改善 (P < 0.05).
结论:
- ViTranZheimer显示了通过非侵入性MRI准确和早期诊断阿尔茨海默病的显著潜力.
- 使用视频视觉转换器为分析复杂的神经成像数据提供了一种新的方法.
- 这种人工智能框架可以作为一种有前途的工具,用于用于神经退行性疾病检测的临床决策支持.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
811
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
811


